WEBINAR | Planning for the Payer: Clinical Trial Design Considerations for Today’s Access & Reimbursement Landscape
In today's pharmaceutical landscape, the value proposition of a drug extends beyond its efficacy for patients and healthcare providers; it also encompasses its impact on payers tasked with managing population health on constrained budgets. Payer consolidation and escalating healthcare costs have underscored the importance of reducing the overall cost of care, making payer considerations essential in clinical trial design.
However, many emerging biotechs focus primarily on scientific innovation, lacking the infrastructure for market access and commercialization expertise. Consequently, trial designs often overlook payer perspectives, jeopardizing successful product commercialization. Ignoring payer considerations not only risks limited access and reimbursement but also potential revenue loss due to unfavorable pricing benchmarks set by key opinion leaders.
In this webinar, experts in market access and clinical development will reveal the results of a survey of payers on their perspectives and priorities, and provide deep insights on how companies can navigate this complex landscape and enhance their chances of securing favorable reimbursement.
In this webinar, attendees will:
- Recognize the critical role of payers as stakeholders in clinical trial design.
- Understand key proof points in clinical programs essential for reimbursement success.
- Learn ways to implement strategies that optimize product pricing, secure payer reimbursement and maximize profitability.
Speakers
Robert Giannetti
Vice President, Global Market Access, Syneos Health
Javier de Renteria
Market Access Lead EU & Emerging Markets, Syneos Health
Rosa Gonzalez
SVP, Head of Product Development Delivery, Syneos Health
Related Content
Want to learn more? Explore Insights Hub for our latest perspectives, subscribe to our podcast, or click the resources below:
Industry Cheers “Co-Pay Accumulator” Ruling, Should Prep for What’s Next
Potential Impact of European Pharma Legislation on Commercialization and Access of New Therapies
